Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1, Open-label, Parallel Group Study to Investigate Olaparib Safety andTolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Protocol ID
D0816C00025
Disease (Sub Disease)
Solid Tumours
Diagnosis Stage
Relapsed/refractory
Location
NSW, WA
Sponsor
AstraZeneca
Links
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
0 Years to 18 Years
International registry ID's
NCT04236414
| Study Title | A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours |
|---|---|
| Protocol ID | D0816C00025 |
| Disease (Sub Disease) | Solid Tumours |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / WA |
| Sponsor | AstraZeneca |
| Links | https://clinicaltrials.gov/ct2/show/NCT04236414 |
| Trial Status | Open |
| Trial Open Date | 01/11/2022 |
| Sites | Perth Children's Hospital / Sydney Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 0 Years to 18 Years |
| International registry ID's | NCT04236414 |